Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | KDM4A | O75164 | 2/20 | 0.31 |
| ▸ | KDM4B | O94953 | 2/20 | 0.31 |
| ▸ | KDM5C | P41229 | 2/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30324511 | 0.87 | HTR2C (0.33) | KDRKDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL9832005 | 0.68 | EGLN2 (0.38) | KDRXDHABL1 | |
| SCHEMBL15739828 | 0.65 | PDE10A (0.38) | PDE10A | |
| SCHEMBL4004452 | 0.65 | HAVCR2 (0.39) | PDE10AXDH | |
| SCHEMBL21895463 | 0.65 | XDH (0.35) | KDRXDHALDH1A1ABL1ADORA2A | |
| SCHEMBL3749203 | 0.65 | NPC1 (0.48) | KDRKDM5BALDH1A1 | |
| SCHEMBL1554373 | 0.63 | AURKA (0.40) | ADORA2AADORA2B | |
| SCHEMBL21895450 | 0.63 | ADORA2A (0.34) | KDRDGAT1PDE10AADORA2AADORA2B | |
| SCHEMBL18520991 | 0.63 | ALDH1A1 (0.40) | XDHALDH1A1ABL1RIN1ADORA2A | |
| SCHEMBL1965382 | 0.63 | AURKA (0.33) | XDHALDH1A1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105261-A1 | Novel substituted pyrazolo[1,5<I>A</I>]-1,3,5-Triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | GREENPHARMA (FR) | 2009-04-23 | — | — | US | claimed |
| WO-2005049615-A1 | PYRAZOLO`1,5-A!`1,3,5! TRIAZIN -4-ONE DERIVATIVES AS CB1 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-06-02 | — | — | WO | claimed |
| US-5358947-A | Treating hypertension, congestive heart failure | AMERICAN CYANAMID COMPANY (US) | 1994-10-25 | — | — | US | claimed |
| US-20250243209-A1 | HETEROCYCLES AS MODULATORS OF NSD ACTIVITY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-07-31 | — | — | US | disclosed |
| CN-119894513-A | Heterocycles as modulators of NSD activity | 德州大学系统董事会 | 2025-04-25 | — | — | CN | disclosed |
| US-12054512-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-08-06 | — | — | US | disclosed |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| CN-117279636-A | Methods and compounds for modulating myotonic muscular dystrophy type 1 | 设计治疗公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-110325543-B | Cyclic dinucleotides as STING (stimulator of interferon genes) agonists | 武田药品工业株式会社 | 2023-03-31 | — | — | CN | disclosed |
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-03 | — | — | US | disclosed |
| CN-114181217-B | Pyrazolo [1,5-a ] [1,3,5] triazine derivative and salt thereof and application of derivative and salt thereof in preparation of anti-cancer drugs | 陕西师范大学 | 2022-12-27 | — | — | CN | disclosed |
| US-20120077814-A1 | SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES | WANG ZHONG (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077814-A1 | SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES | WANG ZHONG (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077814-A1 | SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES | WANG ZHONG (US) | 2012-03-29 | — | — | US | disclosed |
| US-20090105261-A1 | Novel substituted pyrazolo[1,5<I>A</I>]-1,3,5-Triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | GREENPHARMA (FR) | 2009-04-23 | — | — | US | disclosed |
| US-20090105261-A1 | Novel substituted pyrazolo[1,5<I>A</I>]-1,3,5-Triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | GREENPHARMA (FR) | 2009-04-23 | — | — | US | disclosed |
| US-20090105261-A1 | Novel substituted pyrazolo[1,5<I>A</I>]-1,3,5-Triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | GREENPHARMA (FR) | 2009-04-23 | — | — | US | disclosed |
| US-20060106019-A1 | Novel substituted pyrazolo[1,5 a]-1,3,5-triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | GREENPHARMA (FR) | 2006-05-18 | — | — | US | disclosed |
| WO-2005049615-A1 | PYRAZOLO`1,5-A!`1,3,5! TRIAZIN -4-ONE DERIVATIVES AS CB1 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-06-02 | — | — | WO | disclosed |
| US-5358947-A | Treating hypertension, congestive heart failure | AMERICAN CYANAMID COMPANY (US) | 1994-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | STING1, CGAS, MAVS | KDR 3064/4885DGAT1 2398/4885PDE10A 167/4885 |
| US-20120077814-A1 | SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES | NEDD8, NAE1, UBA3 | KDR 4830/4885DGAT1 2097/4885PDE10A 3381/4885 |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | KDR 3064/4885DGAT1 2398/4885PDE10A 167/4885 |
| US-12054512-B2 | Sting modulator compounds, and methods of making and using | STING1, CGAS, MAVS | KDR 3064/4885DGAT1 2398/4885PDE10A 167/4885 |
| US-20060106019-A1 | Novel substituted pyrazolo[1,5 a]-1,3,5-triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | PMP22, BDNF, GRIK5 | KDR 3712/4885DGAT1 3677/4885PDE10A 162/4885 |
| US-20090105261-A1 | Novel substituted pyrazolo[1,5<I>A</I>]-1,3,5-Triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | BDNF, NTRK2, NGF | KDR 109/4885DGAT1 4254/4885PDE10A 234/4885 |
| US-20250243209-A1 | HETEROCYCLES AS MODULATORS OF NSD ACTIVITY | NSD3, NCOA1, NR1D1 | KDR 4052/4885DGAT1 2040/4885PDE10A 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.